{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T13:32:06Z","timestamp":1773235926786,"version":"3.50.1"},"reference-count":13,"publisher":"Cambridge University Press (CUP)","issue":"2-3","license":[{"start":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T00:00:00Z","timestamp":1609891200000},"content-version":"unspecified","delay-in-days":3507,"URL":"https:\/\/www.cambridge.org\/core\/terms"},{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Am. J. Law. Med."],"published-print":{"date-parts":[[2011,6]]},"abstract":"<jats:p>This article provides an overview of how the constitutional protections for commercial speech affect the Food and Drug Administration's (FDA) regulation of drugs, and the emerging issues about the scope of these protections. A federal district court has already found that commercial speech allows manufacturers to distribute reprints of medical articles about a new off-label use of a drug as long as it contains disclosures to prevent deception and to inform readers about the lack of FDA review. This paper summarizes the current agency guidance that accepts the manufacturer's distribution of reprints with disclosures.<\/jats:p><jats:p>Allergan, the maker of Botox, recently maintained in a lawsuit that the First Amendment permits drug companies to provide \u201ctruthful information\u201d to doctors about \u201cwidely accepted\u201d off-label uses of a drug. While the case was settled as part of a fraud and abuse case on other grounds, extending constitutional protections generally to \u201cwidely accepted\u201d uses is not warranted, especially if it covers the use of a drug for a new purpose that needs more proof of efficacy, and that can involve substantial risks.<\/jats:p><jats:p>A health law academic pointed out in an article examining a fraud and abuse case that off-label use of drugs is common, and that practitioners may lack adequate dosage information about the off-label uses. Drug companies may obtain approval of a drug for a narrow use, such as for a specific type of pain, but practitioners use the drug for similar uses based on their experience. The writer maintained that a controlled study may not be necessary to establish efficacy for an expanded use of a drug for pain. Even if this is the case, as discussed below in this paper, added safety risks may exist if the expansion covers a longer period of time and use by a wider number of patients. The protections for commercial speech should not be extended to allow manufacturers to distribute information about practitioner use with a disclosure about the lack of FDA approval. Distributions of information about unapproved uses should not be acceptable unless experts consider the expanded use to be generally recognized as safe and effective based on adequate studies.<\/jats:p><jats:p>The last part of this paper considers the need to develop better research incentives to encourage more testing and post-market risk surveillance by drug makers on off-label uses of their drugs. Violations of the Federal Food Drug and Cosmetic Act (FFDCA) can be considered violations of the False Claims Act, which opens the way to fraud and abuse suits. The scale of penalties involved in these suits may lead to more examination of the scope of FDA regulation and commercial speech protections. Thus this symposium's consideration of these issues is timely and important.<\/jats:p>","DOI":"10.1177\/009885881103700203","type":"journal-article","created":{"date-parts":[[2017,1,11]],"date-time":"2017-01-11T07:09:56Z","timestamp":1484118596000},"page":"258-277","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Commercial Speech and Off-Label Drug Uses: What Role for Wide Acceptance, General Recognition and Research Incentives?"],"prefix":"10.1017","volume":"37","author":[{"given":"Margaret","family":"Gilhooley","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"56","published-online":{"date-parts":[[2021,1,6]]},"reference":[{"key":"S0098858800000307_ref019","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1377\/hlthaff.2010.0504","article-title":"The Supercharged Federal Effort to Crack Down on Fraud and Abuse","volume":"29","author":"Iglehart","year":"2010","journal-title":"Health Aff."},{"key":"S0098858800000307_ref03","first-page":"826","article-title":"Constitutionalizing Food and Drug Law","volume":"74","author":"Gilhooley","year":"2000","journal-title":"Tul. L. Rev."},{"key":"S0098858800000307_ref093","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1056\/NEJMsb0708920","article-title":"Pharmaceutical Promotion to Physicians and First Amendment Rights","volume":"358","author":"Kesselheim","year":"2008","journal-title":"New Eng. J. Med."},{"key":"S0098858800000307_ref051","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1056\/NEJMhle0807695","article-title":"Shifting Terrain in the Regulation of Off-Label Promotion of Pharmaceuticals","volume":"360","author":"Mello","year":"2009","journal-title":"New Eng. J. Med."},{"key":"S0098858800000307_ref044","first-page":"866","article-title":"Drug Safety and Commercial Speech: Television Advertisements and Reprints on Off-Label Uses","volume":"47","author":"Gilhooley","year":"2010","journal-title":"San Diego L. Rev."},{"key":"S0098858800000307_ref092","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1001\/archinte.166.9.1021","article-title":"Off-Label Prescribing Among Office-Based Physicians","volume":"166","author":"Radley","year":"2006","journal-title":"Archives of Internal Med."},{"key":"S0098858800000307_ref0017","first-page":"941","article-title":"Vioxx\u2019s History and the Need for Better Procedures and Better Testing","volume":"37","author":"Gilhooley","year":"2007","journal-title":"Seton Hall L. Rev."},{"key":"S0098858800000307_ref08","first-page":"73","article-title":"Polluting Medical Judgment? False Assumptions in the Pursuit of False Claims Regarding Off-Label Prescribing","volume":"9","author":"Johnson","year":"2008","journal-title":"Minn. J. of L. Sci. and Tech. 61,"},{"key":"S0098858800000307_ref017","first-page":"350","article-title":"Addressing Potential Drug Risks: The Limits of Testing, Risk Signals, Preemption and the Drug Reform Legislation","volume":"59","author":"Gilhooley","year":"2008","journal-title":"S.C. L. Rev."},{"key":"S0098858800000307_ref046","first-page":"347","article-title":"Thoughts on Commercial Speech: A Roundtable Discussion","volume":"41","year":"2007","journal-title":"Loy. L.A. L. Rev."},{"key":"S0098858800000307_ref030","first-page":"921","article-title":"Drug Regulation and the Constitution","volume":"37","author":"Gilhooley","year":"2003","journal-title":"U. Rich. L. Rev."},{"key":"S0098858800000307_ref021","first-page":"301","article-title":"Can I Tell You the Truth? A Comparative Perspective on Regulating Off-Label Scientific and Medical Information?","volume":"10","author":"Osborn","year":"2010","journal-title":"Yale J. Health Pol\u2019y L. and Ethics"},{"key":"S0098858800000307_ref0106","first-page":"26","article-title":"Heal the Damage: Prescription Drug Consumer Advertisements and Relative Choices","volume":"38","author":"Gilhooley","year":"2005","journal-title":"J. Health L. 1,"}],"container-title":["American Journal of Law &amp; Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/009885881103700203","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0098858800000307","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T03:33:39Z","timestamp":1609904019000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0098858800000307\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6]]},"references-count":13,"journal-issue":{"issue":"2-3","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["S0098858800000307"],"URL":"https:\/\/doi.org\/10.1177\/009885881103700203","relation":{},"ISSN":["0098-8588","2375-835X"],"issn-type":[{"value":"0098-8588","type":"print"},{"value":"2375-835X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,6]]}}}